This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greenberg, P. L. Articles by Mosny, S. A. Search for Related Content PubMed PubMed Citation Articles by Greenberg, P. L. Articles by Mosny, S. A.

Cytotoxic Effects of Interferon in Vitro on Granulocytic Progenitor Cells¹

Department of Medicine, Veterans Administration Hospital and Stanford University School of Medicine, Palo Alto, California 94304

We have utilized in vitro marrow culture techniques to evaluate the cytotoxicity for granulocytic progenitor cells of two highly purified human leukocyte interferon preparations. Concentration- and time-related decrements in granulocytic colony-forming capacity in agar occurred with human and mouse marrow. Although mouse marrow cells were less sensitive than were human cells, these data indicate lack of strict species specificity for the cell growth-inhibitory effects of interferon. Similar cytotoxicity was noted for normal and leukemic human clonogenic cells exposed to interferon for prolonged periods. The decrease in the proportion of granulocytic progenitor cells in DNA synthesis, which occurred at high concentrations, and the diminution by interferon of the cytotoxicity caused by cytosine arabinoside demonstrate that interferon decreases DNA synthesis of granulocytic progenitor cells. The lack of enhanced cytotoxicity for rapidly proliferating mouse post-endotoxin marrow cells indicates that interferon is not a cell cycle-stage-specific drug. These data seem useful for evaluating the suppressive effects of interferon on granulopoiesis and for devising clinical trials with this agent.

¹ Supported by Grant CA13141 from the National Cancer Institute; by Grant AI-05629 from the National Institute of Allergy and Infectious Diseases, NIH, USPHS; and by the Medical Research Service of the Veterans Administration.

² Scholar, Leukemia Society of America, Inc. To whom requests for reprints should be addressed.

Received 12/30/76. Accepted 3/17/77.

This article has been cited by other articles:

				B. L. McRae, T. Nagai, R. T. Semnani, J. M. van Seventer, and G. A. van Seventer Interferon-alpha and -beta inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14+ precursors Blood, July 1, 2000; 96(1): 210 - 217. [Abstract] [Full Text] [PDF]

				M. TALPAZ, G. MAVLIGIT, M. KEATING, R. S. WALTERS, and J. U. GUTTERMAN Human Leukocyte Interferon to Control Thrombocytosis in Chronic Myelogenous Leukemia Ann Intern Med, December 1, 1983; 99(6): 789 - 792. [Abstract] [PDF]

				J. U. GUTTERMAN, G. R. BLUMENSCHEIN, R. ALEXANIAN, H.-Y. YAP, A. U. BUZDAR, F. CABANILLAS, G. N. HORTOBAGYI, E. M. HERSH, S. L. RASMUSSEN, M. HARMON, et al. Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma Ann Intern Med, September 1, 1980; 93(3): 399 - 406. [Abstract] [PDF]

				E. C. BORDEN Interferons: Rationale for Clinical Trials in Neoplastic Disease Ann Intern Med, September 1, 1979; 91(3): 472 - 479. [Abstract] [PDF]